Shares of Medigus Ltd. (NASDAQ: MDGS ), an Israel-based medical device company that focuses on developing minimally invasive endo-surgical tools, gained more than 11 percent early Thursday morning after ...
Further to the company’s previous reports, the company’s management and board of directors continue to decrease inefficiencies, expand the company’s revenue streams and pursue diversification of its activity portfolio.
Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, announced today that it has received a patent from the US Patent for its innovative ScoutCam™ Micro-Visual Technology. The U.S patent number is 10,188,275 and it is titled Small Diameter Video Camera Heads and Visualization Probes and Medical Devices Containing Them. The patent refers to small diameter camera heads and small diameter visualization probes with a maximal diameter of 4mm, and small diameter medical devices containing visualization means with a maximal diameter of 4mm.
Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, announced today that it has filed an application under the framework of a consortium for a European grant for the development of a fluorescent colonoscope from Horizon 2020 fund. The expected duration of the project is four years, and its budget is 3,000,000 Euros and its intention is to improve the ability of early detection of colorectal cancer. In addition to Medigus, three universities from Germany and the Netherlands (Helmholtz Zentrum München, Technical University of Munich, University Medical Center Groningen) and a German company (Amcure), are parties to the consortium.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9: China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...
OMER, Israel, Jan. 10, 2019 (GLOBE NEWSWIRE) -- (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, announced today that Mr. Chris Rowland, the company’s chief executive officer, will step down effective as of February 28, 2019. Following such date, Mr. Rowland will continue to work with the company as a consultant to contribute from his experience and understanding of the company’s products to promoting shareholder value through the MUSE™ and ScoutCam™ portfolios. Chris Rowland was appointed chief executive officer of Medigus in October 2013 and has since played a key role in the development and commercialization of the Company’s products.
Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that it is in advanced negotiations to grant a license or licenses to its MUSE™ technology Globally and/or in greater China. For this purpose, Medigus commenced advanced talks with relevant multi-national medical device companies and is expected to receive upfront payments that may add up to millions of U.S. dollars should such transactions close.
Medigus Ltd. (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the National Aeronautics and Space Administration (NASA), has incorporated Medigus’ micro ScoutCam™ 8.0 HD, the world’s smallest HD camera and illumination solution, into its Visual Inspection Poseable Invertebrate Robot 2 (VIPIR2). VIPIR2, a robotic, multi-capability inspection tool being used as part of NASA’s Robotic Refueling Mission 3 (RRM3), was launched into space on December 5, 2018.
Medigus Ltd. (“Medigus” or the “Company”) (MDGS) (MDGS.TA), a medical device company developing minimally invasive endosurgical tools and direct visualization technology, today announced financial results for the third quarter ended September 30, 2018. “Following our third quarter results we look forward to future milestones for Medigus to increase the Company’s core business and create shareholder value. In August 2018, the Company announced distribution agreement with Micro-Tech Endoscopy USA, representing a significant milestone for Medigus in the US market.
Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.